Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.

Bocchia M, Candoni A, Borlenghi E, Defina M, Filì C, Cattaneo C, Sammartano V, Fanin R, Sciumè M, Sicuranza A, Imbergamo S, Riva M, Fracchiolla N, Latagliata R, Caizzi E, Mazziotta F, Alunni G, Di Bona E, Crugnola M, Rossi M, Consoli U, Fontanelli G, Greco G, Nadali G, Rotondo F, Todisco E, Bigazzi C, Capochiani E, Molteni A, Bernardi M, Fumagalli M, Rondoni M, Scappini B, Ermacora A, Simonetti F, Gottardi M, Lambertenghi Deliliers D, Michieli M, Basilico C, Galeone C, Pelucchi C, Rossi G.

Hematol Oncol. 2019 Aug 5. doi: 10.1002/hon.2663. [Epub ahead of print]

PMID:
31385337
2.

Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?

Nucci M, Shoham S, Abdala E, Hamerschlak N, Rico JC, Forghieri F, Nouér SA, Cappellano P, Solza C, Gonzaga Y, Nadali G, Nucci F, Colombo AL, Albuquerque AM, Queiroz-Telles Filho F, Lima CBL, Arrais-Rodrigues C, Rocha V, Marty FM.

Mycoses. 2019 May;62(5):413-417. doi: 10.1111/myc.12901.

PMID:
30720902
3.

'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.

Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, Delia M, Potenza L, Farina F, Ballanti S, Decembrino N, Castagnola C, Nadali G, Fanci R, Orciulo E, Veggia B, Offidani M, Melillo L, Manetta S, Tumbarello M, Venditti A, Busca A, Aversa F, Pagano L; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group .

J Antimicrob Chemother. 2019 Apr 1;74(4):1062-1068. doi: 10.1093/jac/dky550.

PMID:
30649413
4.

Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.

Efficace F, Breccia M, Avvisati G, Cottone F, Intermesoli T, Borlenghi E, Carluccio P, Rodeghiero F, Fabbiano F, Luppi M, Romani C, Sborgia M, D'Ardia S, Nobile F, Cantore N, Crugnola M, Nadali G, Vignetti M, Amadori S, Lo Coco F.

Leukemia. 2019 Jul;33(7):1598-1607. doi: 10.1038/s41375-018-0325-4. Epub 2018 Dec 20.

PMID:
30573776
5.

Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases.

Candoni A, Klimko N, Busca A, Di Blasi R, Shadrivova O, Cesaro S, Zannier ME, Verga L, Forghieri F, Calore E, Nadali G, Simonetti E, Muggeo P, Quinto AM, Castagnola C, Cellini M, Del Principe MI, Fracchiolla N, Melillo L, Piedimonte M, Zama D, Farina F, Giusti D, Mosna F, Capelli D, Delia M, Picardi M, Decembrino N, Perruccio K, Vallero S, Aversa F, Fanin R, Pagano L; SEIFEM Group (Epidemiological Surveillance of Infections in Haematological Diseases).

Mycoses. 2019 Mar;62(3):252-260. doi: 10.1111/myc.12884. Epub 2019 Jan 22.

PMID:
30565742
6.

Rhodotorula infection in haematological patient: Risk factors and outcome.

Potenza L, Chitasombat MN, Klimko N, Bettelli F, Dragonetti G, Del Principe MI, Nucci M, Busca A, Fracchiolla N, Sciumè M, Spolzino A, Delia M, Mancini V, Nadali GP, Dargenio M, Shadrivova O, Bacchelli F, Aversa F, Sanguinetti M, Luppi M, Kontoyiannis DP, Pagano L.

Mycoses. 2019 Mar;62(3):223-229. doi: 10.1111/myc.12875. Epub 2018 Dec 28.

PMID:
30525252
7.

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.

Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R.

Leuk Res. 2019 Jan;76:33-38. doi: 10.1016/j.leukres.2018.11.015. Epub 2018 Nov 28.

PMID:
30529681
8.

Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs.

Facchinelli D, Marchesini G, Nadali G, Pagano L.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018063. doi: 10.4084/MJHID.2018.063. eCollection 2018. Review.

9.

Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.

Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, Delia M, Ballanti S, Marchesi F, Mancini V, Orciuolo E, Cesaro S, Prezioso L, Fanci R, Nadali G, Chierichini A, Facchini L, Picardi M, Malagola M, Orlando V, Trecarichi EM, Tumbarello M, Aversa F, Rossi G, Pagano L; SEIFEM Group.

Ann Hematol. 2018 Sep;97(9):1717-1726. doi: 10.1007/s00277-018-3341-6. Epub 2018 Apr 28.

PMID:
29705860
10.

Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).

Di Blasi R, Cattaneo C, Lewis RE, Tumbarello M, Angelici L, Dragonetti G, Busca A, Cambò B, Candoni A, Cesarini M, Cesaro S, Delia M, Fanci R, Farina F, Garzia M, Giordano A, Martino B, Melillo L, Nadali G, Perriello V, Picardi M, Quinto AM, Salutari P, Spolzino A, Vacca A, Vetro C, Zancanella M, Nosari A, Aversa F, Pagano L; on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia).

Ann Hematol. 2018 May;97(5):791-798. doi: 10.1007/s00277-018-3252-6. Epub 2018 Feb 7.

PMID:
29411126
11.

Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report.

Pagano L, Dragonetti G, Cattaneo C, Marchesi F, Veggia B, Busca A, Candoni A, Prezioso L, Criscuolo M, Cesaro S, Delia M, Fanci R, Stanzani M, Ferrari A, Martino B, Melillo L, Nadali G, Simonetti E, Ballanti S, Picardi M, Castagnola C, Decembrino N, Gazzola M, Fracchiolla NS, Mancini V, Nosari A, Principe MID, Aversa F, Tumbarello M; SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia).

Haematologica. 2017 Oct;102(10):e407-e410. doi: 10.3324/haematol.2017.172536. Epub 2017 Jul 20. No abstract available.

12.

SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.

Busca A, Lessi F, Verga L, Candoni A, Cattaneo C, Cesaro S, Dragonetti G, Delia M, De Luca A, Guglielmi G, Tumbarello M, Martino G, Nadali G, Fanci R, Picardi M, Potenza L, Nosari A, Aversa F, Pagano L; on the behalf of the SEIFEM Group (Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne).

Leuk Lymphoma. 2017 Dec;58(12):2859-2864. doi: 10.1080/10428194.2017.1318438. Epub 2017 May 16.

PMID:
28508692
13.

Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.

Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, Fianchi L, Delia M, Sica S, Perriello V, Busca A, Aversa F, Fanci R, Melillo L, Lessi F, Del Principe MI, Cattaneo C, Tumbarello M; HaematologicMalignancies Associated Bloodstream Infections Surveillance (HEMABIS) registry - Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne(SEIFEM) group, Italy.

Am J Hematol. 2016 Nov;91(11):1076-1081. doi: 10.1002/ajh.24489. Epub 2016 Jul 29.

14.

Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations.

Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, Nadali G, Potenza L, Russo D, Tumbarello M, Nosari A, Aversa F; SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne) Group; Other Authors:.

Blood Rev. 2017 Mar;31(2):17-29. doi: 10.1016/j.blre.2016.09.002. Epub 2016 Sep 17. Review.

PMID:
27682882
15.

Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.

Lazzarotto D, Candoni A, Nadali G, Pavan L, Lessi F, Mosna F, Simeone E, Ventura G, Gherlinzoni F, Semenzato G, Pizzolo G, Fanin R.

Eur J Haematol. 2016 Jun;96(6):586-92. doi: 10.1111/ejh.12635. Epub 2015 Aug 17.

PMID:
26186084
16.

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).

Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, Caramatti C, Castagnola C, Cattaneo C, Fanci R, Chierichini A, Melillo L, Mitra ME, Picardi M, Potenza L, Salutari P, Vianelli N, Facchini L, Cesarini M, De Paolis MR, Di Blasi R, Farina F, Venditti A, Ferrari A, Garzia M, Gasbarrino C, Invernizzi R, Lessi F, Manna A, Martino B, Nadali G, Offidani M, Paris L, Pavone V, Rossi G, Spadea A, Specchia G, Trecarichi EM, Vacca A, Cesaro S, Perriello V, Aversa F, Tumbarello M, Pagano L; SEIFEM Group (Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne).

Haematologica. 2015 Feb;100(2):284-92. doi: 10.3324/haematol.2014.113399.

17.

Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry.

Pagano L, Stamouli M, Tumbarello M, Verga L, Candoni A, Cattaneo C, Nadali G, Mitra ME, Mancini V, Nosari A, Garzia MG, Delia M, Storti S, Spadea A, Caramatti C, Perriello V, Sanna M, Vacca A, De Paolis MR, Potenza L, Salutari P, Castagnola C, Fanci R, Chierichini A, Melillo L, Picardi M, Facchini L, Martino B, Di Blasi R, Cesarini M, Offidani M, Vianelli N, Caira M, Lessi F, Ferrari A, Venditti A, Pavone V, Lo-Coco F, Aversa F, Busca A; Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne Group.

Br J Haematol. 2015 Aug;170(3):434-9. doi: 10.1111/bjh.13308. Epub 2015 Jan 27. No abstract available.

PMID:
25626374
18.

Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.

Pagano L, Verga L, Busca A, Martino B, Mitra ME, Fanci R, Ballanti S, Picardi M, Castagnola C, Cattaneo C, Nadali G, Nosari A, Candoni A, Caira M, Salutari P, Lessi F, Aversa F, Tumbarello M.

J Antimicrob Chemother. 2014 Nov;69(11):3142-7. doi: 10.1093/jac/dku227. Epub 2014 Jun 19.

PMID:
24948702
19.

Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.

Cairoli R, Beghini A, Turrini M, Bertani G, Nadali G, Rodeghiero F, Castagnola C, Lazzaroni F, Nichelatti M, Ferrara F, Pizzolo G, Pogliani E, Rossi G, Martinelli G, Morra E.

Am J Hematol. 2013 Jul;88(7):594-600. doi: 10.1002/ajh.23461. Epub 2013 Jun 5.

20.

Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.

Pagano L, Caira M, Candoni A, Aversa F, Castagnola C, Caramatti C, Cattaneo C, Delia M, De Paolis MR, Di Blasi R, Di Caprio L, Fanci R, Garzia M, Martino B, Melillo L, Mitra ME, Nadali G, Nosari A, Picardi M, Potenza L, Salutari P, Trecarichi EM, Tumbarello M, Verga L, Vianelli N, Busca A; SEIFEM Group.

Clin Infect Dis. 2012 Dec;55(11):1515-21. doi: 10.1093/cid/cis773. Epub 2012 Sep 5.

PMID:
22955439
21.

Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia.

Cairoli R, Ripamonti CB, Beghini A, Granata S, Grillo G, Brioschi M, Nadali G, Viola A, Cattaneo C, Inropido L, Ravelli E, Bertani G, Pezzetti L, Nichelatti M, Marocchi A, Rossi G, Pizzolo G, Ferrara F, Nosari AM, Morra E.

Leuk Res. 2009 Sep;33(9):1282-4. doi: 10.1016/j.leukres.2009.03.043. Epub 2009 Apr 29.

PMID:
19406474
22.

Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation.

Trojani A, Ripamonti CB, Penco S, Beghini A, Nadali G, Di Bona E, Viola A, Castagnola C, Colapietro P, Grillo G, Pezzetti L, Ravelli E, Patrosso MC, Marocchi A, Cuneo A, Ferrara F, Lazzarino M, Pizzolo G, Cairoli R, Morra E.

Anticancer Res. 2008 Sep-Oct;28(5A):2745-51.

23.

High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.

Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA.

Br J Haematol. 2007 Jun;137(6):553-9.

PMID:
17539776
24.

beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens.

Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA.

J BUON. 2005 Jan-Mar;10(1):59-69.

25.

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.

Visco C, Nadali G, Vassilakopoulos TP, Bonfante V, Viviani S, Gianni AM, Federico M, Luminari S, Peethambaram P, Witzig TE, Pangalis G, Cabanillas F, Medeiros LJ, Sarris AH, Pizzolo G.

Eur J Haematol. 2006 Nov;77(5):387-94. Epub 2006 Jul 27.

PMID:
16879607
26.

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E.

Blood. 2006 May 1;107(9):3463-8. Epub 2005 Dec 29.

27.

Serum levels of soluble syndecan-1 in Hodgkin's lymphoma.

Vassilakopoulos TP, Kyrtsonis MC, Papadogiannis A, Nadali G, Angelopoulou MK, Tzenou T, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Kalpadakis C, Kokoris SI, Dimitriadou EM, Tsaftaridis P, Pizzolo G, Pangalis GA.

Anticancer Res. 2005 Nov-Dec;25(6C):4743-6.

28.

Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy.

Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, Medeiros LJ, Notti P, Rassidakis GZ, Peethambaram P, Wilder R, Witzig T, Gianni M, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH.

Leuk Lymphoma. 2004 Oct;45(10):2085-92.

PMID:
15370254
29.

Effect of addition of FLT-3 ligand and megakaryocyte growth and development factor on hemopoietic cells in serum-free conditions.

Rossi B, Zanolin E, Vincenzi C, Diani F, Pizzolo G, de Wynter E, Nadali G.

Stem Cells Dev. 2004 Aug;13(4):362-71.

PMID:
15345130
30.

KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.

Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F, Nadali G, Grillo G, Haas OA, Biondi A, Morra E, Larizza L.

Haematologica. 2004 Aug;89(8):920-5.

31.

Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7.

Scupoli MT, Vinante F, Krampera M, Vincenzi C, Nadali G, Zampieri F, Ritter MA, Eren E, Santini F, Pizzolo G.

Haematologica. 2003 Nov;88(11):1229-37.

32.

Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome.

Herling M, Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, Giardini R, Chilosi M, Kittas C, Gianni AM, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH.

Clin Cancer Res. 2003 Jun;9(6):2114-20.

33.

G-CSF-stimulated neutrophils are a prominent source of functional BLyS.

Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, Cassatella MA.

J Exp Med. 2003 Feb 3;197(3):297-302.

34.

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma.

Zanotti R, Trolese A, Ambrosetti A, Nadali G, Visco C, Ricetti MM, Benedetti F, Pizzolo G.

Ann Oncol. 2002 Dec;13(12):1908-14.

PMID:
12453859
35.

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.

Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McDonnell TJ, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH.

Blood. 2002 Dec 1;100(12):3935-41.

36.

The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.

Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Karkantaris C, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Pizzolo G, Pangalis GA.

Haematologica. 2002 Jul;87(7):701-8; discussion 708.

37.

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.

Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, Mesina O, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McLaughlin P, Rodriguez MA, Romaguera J, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH.

J Clin Oncol. 2002 Mar 1;20(5):1278-87.

PMID:
11870170
38.

BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome.

Rassidakis GZ, Medeiros LJ, McDonnell TJ, Viviani S, Bonfante V, Nadali G, Vassilakopoulos TP, Giardini R, Chilosi M, Kittas C, Gianni AM, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH.

Clin Cancer Res. 2002 Feb;8(2):488-93.

39.

Multi-resistant idiopathic thrombocytopenia successfully treated by eradication of Helicobacter pylori.

Soldinger E, Pilia MC, Piubello W, Nadali G.

Dig Liver Dis. 2001 Nov;33(8):732. No abstract available.

PMID:
11785722
40.

Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma.

Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Rassidakis GZ, Doussis-Anagnostopoulou IA, Hatzioannou M, Vaiopoulos G, Kittas C, Sarris AH, Pizzolo G, Pangalis GA.

Haematologica. 2001 Mar;86(3):274-81.

41.

Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.

Corato A, Ambrosetti A, Rossi B, Vincenzi C, Lambiase A, Perona G, Pizzolo G, de Wynter E, Nadali G.

J Hematother Stem Cell Res. 2000 Oct;9(5):673-82.

PMID:
11091491
42.

Intracellular cytokine profile of cord blood T-, and NK- cells and monocytes.

Krampera M, Tavecchia L, Benedetti F, Nadali G, Pizzolo G.

Haematologica. 2000 Jul;85(7):675-9.

43.

PCR with degenerate primers for highly conserved DNA polymerase gene of the herpesvirus family shows neither human herpesvirus 8 nor a related variant in bone marrow stromal cells from multiple myeloma patients.

Dominici M, Luppi M, Campioni D, Lanza F, Barozzi P, Milani R, Moretti S, Nadali G, Spanedda R, Trovato R, Torelli G, Castoldi G.

Int J Cancer. 2000 Apr 1;86(1):76-82.

44.

Multicentre European study comparing selection techniques for the isolation of CD34+ cells.

de Wynter EA, Ryder D, Lanza F, Nadali G, Johnsen H, Denning-Kendall P, Thing-Mortensen B, Silvestri F, Testa NG.

Bone Marrow Transplant. 1999 Jun;23(11):1191-6.

45.

Regulation of the proliferative potential of cord blood long-term culture-initiating cells (LTC-IC) by different stromal cell lines: implications for LTC-IC measurement.

Nadali G, de Wynter EA, Perandin F, Tavecchia L, Vincenzi C, Ambrosetti A, Fornalè M, Perona G, Pizzolo G, Testa NG.

Haematologica. 1998 Dec;83(12):1059-65.

46.

Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome.

Vinante F, Rigo A, Tecchio C, Morosato L, Nadali G, Ricetti MM, Krampera M, Zanolin E, Locatelli F, Gallati H, Chilosi M, Pizzolo G.

Br J Haematol. 1998 Sep;102(4):1025-34.

PMID:
9734654
47.

The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy.

Dammacco F, Silvestris F, Castoldi GL, Grassi B, Bernasconi C, Nadali G, Perona G, De Laurenzi A, Torelli U, Ascari E, Rossi Ferrini PL, Caligaris-Cappio F, Pileri A, Resegotti L.

Int J Clin Lab Res. 1998;28(2):127-34.

PMID:
9689556
48.

Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.

Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G.

Blood. 1998 Apr 15;91(8):3011-6.

49.

Soluble molecules as biological markers in Hodgkin's disease.

Nadali G, Vinante F, Chilosi M, Pizzolo G.

Leuk Lymphoma. 1997 Dec;26 Suppl 1:99-105.

PMID:
9570686
50.

High serum level of soluble CD30 in acute primary HIV-1 infection.

Pizzolo G, Vinante F, Nadali G, Krampera M, Morosato L, Chilosi M, Raiteri R, Sinicco A.

Clin Exp Immunol. 1997 May;108(2):251-3.

Supplemental Content

Loading ...
Support Center